Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Functional VEGF-A (human) Antibody, mAb
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | P15692 |
| Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | Mouse IgG1 |
| Gene Source | Human |
| Application Note | ,E(1-15 µg/ml),Functional Application,Neutralization,WB(2-10 µg/ml), |
| Clone Names | 3(6D3) |
| Calculated MW | 43597 Da |
| Gene ID | 7422 |
|---|---|
| Other Names | Vascular Endothelial Growth Factor-A; VPF |
| Format | Lyophilized. |
| Reconstitution & Storage | Stable for at least 6 months after receipt when stored at -20°C. |
| Precautions | Functional VEGF-A (human) Antibody, mAb is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | VEGFA |
|---|---|
| Synonyms | VEGF |
| Function | [N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia- mediated cell death (By similarity). |
| Cellular Location | [N-VEGF]: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxic conditions and localizes to the nucleus under hypoxic conditions [Isoform L-VEGF189]: Endoplasmic reticulum. Golgi apparatus. Secreted, extracellular space, extracellular matrix [Isoform VEGF165]: Secreted |
| Tissue Location | Higher expression in pituitary tumors than the pituitary gland. [Isoform VEGF165]: Widely expressed. [Isoform VEGF206]: Not widely expressed. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Human vascular endothelial erowth factor (VEGF 165) is produced as a homodimer. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. VEGF-A is a specific mitogen for vascular endothelial cells and a strong angiogenic factor in vivo. In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo. It is also a chemoattractant molecule for monocytes and endothelial cells. It induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
